TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04428515

Intervention type: DEVICE
Intervention: Photoacoustic Imaging System
Description: Photoacoustic Imaging investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer
Study: NCT03924206

Intervention type: DEVICE
Intervention: Smoke evacuation system
Description: The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated

Intervention type: DEVICE
Intervention: Smoke evacuation system
Description: The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
Study: NCT01267721

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling at various time points. Additional 92 mL blood.
Study: NCT04091711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReX-C system
Description: Oral oncolytic medications are dispensed to patients via ReX-C system
Study: NCT01998958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Description: 1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine 84 mg
Description: 1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
Study: NCT02393443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
Study: NCT01998958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
Study: NCT00426712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen
Description: Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen
Description: Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen
Description: Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine (Recombinant)
Description: IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
Study: NCT04581174

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Description: Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Description: Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Description: Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated
Description: Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
Study: NCT01570803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S.M.A.R.T CONTROL Stent
Description: Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete SE Stent
Description: same to SMART CONTROL Stent
Study: NCT01998958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
Study: NCT01261052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm
Description: The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Adaptive Proportional Derivative Algorithm
Description: The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin.
Study: NCT03401372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Oral doxycycline 100mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
Study: NCT04283500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Naloxone
Description: Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
Study: NCT02761005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Description: For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Description: For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
Study: NCT02392351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (Vessix)
Description: Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Renal Angiography
Description: Percutaneous renal angiography
Study: NCT00963560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSTOR +3
Description: Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crystalens HD
Description: Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crystalens AO
Description: Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
Study: NCT01851200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
Study: NCT04358289

Intervention type: OTHER
Group type: OTHER
Intervention: Basic antimicrobial stewardship education
Description: Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
Study: NCT04992585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic implantation of self-expandable metal stent
Description: A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transhepatic implantation of self-expandable metal stent
Description: A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
Study: NCT03450434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 Oral Tablet
Description: 1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 Oral Tablet
Description: 1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 Oral Tablet
Description: 1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
Study: NCT02721901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iEAT Manual Intervention
Description: The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
Study: NCT00044655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: As prescribed by routine prescriber (not dictated by study protocol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: As prescribed by routine prescriber (not dictated by study protocol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: As prescribed by routine prescriber (not dictated by study protocol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: As prescribed by routine prescriber (not dictated by study protocol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: As prescribed by routine prescriber (not dictated by study protocol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: As prescribed by routine prescriber (not dictated by study protocol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: As prescribed by routine prescriber (not dictated by study protocol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: As prescribed by routine prescriber (not dictated by study protocol)
Study: NCT03337867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Super Rapid2 System
Description: Intermittent theta-burst-stimulation (iTBS) protocol

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Super Rapid2 System
Description: Sham stimulation
Study: NCT04401150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
Study: NCT01144169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HC)
Description: Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
Study: NCT04247893

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: blood flow restriction
Description: Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blood flow restriction
Description: Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo photobiomodulation
Description: Placebo photobiomodulation - photobiomodulation device turned off.
Study: NCT04266392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-DCFPyl Ligand
Description: To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
Study: NCT01780844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: intravenous or oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: intravenous or oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: intravenous or oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: intravenous or oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisone
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral
Study: NCT01897727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: BP medication uptitration
Description: antihypertensive medication added or uptitrated following standard of care
Study: NCT00958360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Low Vision Service
Description: Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic Low Vision Service
Description: Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.